|
 Shares of Seattle Genetics were up 6% at $119.05 after the bell.
The drug, Padcev, is the first FDA approved treatment in the United
States for patients with advanced or metastatic urothelial cancer,
the companies said.
The drug will treat patients with advanced bladder cancer whose
disease has progressed even after treatment with immunotherapy and
chemotherapy. (https://bit.ly/38RgSSf)
The American Cancer Society estimates 17,670 people will die from
bladder cancer in the United States this year.
[to top of second column] |
The continued approval of the drug may depend upon verification of
clinical benefit in confirmatory trials, the companies said, adding
that a late-stage study is underway.
The FDA's accelerated approval program allows conditional approval
of a medicine that fills an unmet medical need for a serious
condition.
(Reporting by Dania Nadeem in Bengaluru; Editing by Aditya Soni)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
